Note: The physicians from Pennington Cancer Center at Baton Rouge General cannot provide a diagnosis or medical advice in the Ask the Expert segment because they do not have thorough knowledge of relevant personal and family medical history, and a physical examination. They can respond to general questions about cancer and its treatment.
Question - I have heard of a new breast cancer study looking at cancer genes to decide on the best treatment. Can you tell me anything about it?
The Pennington Cancer Center at Baton Rouge General is participating in the Trial Assigning Individualized Options for Treatment (Rx). This investigational trial, also known as TAILORx, is studying whether certain genes found in early-stage breast cancer can be used to assign patients to the most effective therapy. TAILORx is one of the first investigational trials studying personalized cancer treatment.
TAILORx utilizes a molecular profiling test done on tumor tissue (Oncotype DX Breast Cancer Assay). The assay examines 21 genes simultaneously. The results are reported as a Recurrence Score and used to predict which patients are likely to benefit from the addition of chemotherapy to hormone therapy. The study will enroll over 10,000 women at 900 sites in the United States and Canada.
Women with recently diagnosed breast cancer may be eligible for the study if the tumor is estrogen-receptor and/or progesterone-receptor positive, Her2/neu-negative and has not yet spread to the lymph nodes under the arm.
TAILORx is sponsored by the National Cancer Institute (NCI)and is coordinated by the Eastern Cooperative Oncology Group.
For additional information, contact the cancer research department at Pennington Cancer Center: (225) 381-6451.